Get the Stockscreener App
2.99
1.97%
-0.06
Rocket Pharmaceuticals Inc stock is traded at $2.99, with a volume of 1.89M.
It is down -1.97% in the last 24 hours and up +15.44% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
See More
Previous Close:
$3.05
Open:
$3.05
24h Volume:
1.89M
Relative Volume:
0.39
Market Cap:
$319.29M
Revenue:
-
Net Income/Loss:
$-258.08M
P/E Ratio:
-1.0873
EPS:
-2.75
Net Cash Flow:
$-202.32M
1W Performance:
-4.78%
1M Performance:
+15.44%
6M Performance:
-72.16%
1Y Performance:
-86.55%
1-Day Range:
$2.9644
$3.05
1-Week Range:
$2.9644
$3.36
52-Week Range:
$2.19
$22.01
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
2.99 | 328.60M | 0 | -258.08M | -202.32M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-30-25 | Downgrade | Evercore ISI | Outperform → In-line |
| May-28-25 | Downgrade | Goldman | Neutral → Sell |
| May-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-28-25 | Downgrade | Jefferies | Buy → Hold |
| May-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-28-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-27-25 | Downgrade | Needham | Buy → Hold |
| May-27-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Dec-30-24 | Initiated | Wedbush | Outperform |
| Dec-18-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-23 | Initiated | Morgan Stanley | Overweight |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Nov-01-22 | Initiated | BTIG Research | Buy |
| Jul-08-22 | Initiated | Raymond James | Outperform |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Feb-18-21 | Initiated | Needham | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-02-20 | Initiated | JP Morgan | Overweight |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-26-19 | Initiated | Piper Jaffray | Overweight |
| Apr-23-19 | Initiated | Robert W. Baird | Outperform |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Feb-05-19 | Initiated | Oppenheimer | Outperform |
| Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
| Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
מועד אחרון חשוב לתביעה נגד RCKT: רוזן, משרד ארצי מוביל, מעודד משקיעים ב- Rocket Pharmaceuticals, Inc עם הפסדים של יותר מ-100 אלף דולר להבטיח ייעוץ לפני המועד האחרון החשוב של 11 באוגוסט בתביעה ייצוגית בניירות ערך - GlobeNewswire Inc.
RCKT IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL FIRM Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action – RCKT - GlobeNewswire Inc.
Rocket Pharmaceuticals, Inc. Investors: Please contact the - GlobeNewswire
Deadline Alert: Rocket Pharmaceuticals, Inc. (RCKT) - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesRCKT - FinancialContent
Levi & Korsinsky Urges Rocket (RCKT) Shareholders to Act Before Lead Plaintiff Deadline August 11, 2025 - Barchart.com
RCKT 10-DAY DEADLINE ALERT: FDA Clinical Hold on RP-A501 - GlobeNewswire
The Double-Edged Sword of Biotech Innovation: Assessing Legal and Regulatory Risks in the Rocket Pharmaceuticals Saga - AInvest
Rocket Pharmaceuticals Restructures, Lays Off 30% of Workforce to Focus on Cardiovascular, LAD-I Gene Therapies - Insider Monkey
RCKT Deadline: RCKT Investors with Losses in Excess of $100K Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - WV News
Investors in Rocket Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before August 11, 2025 to Discuss Your RightsRCKT - Barchart.com
Investors in Rocket Pharmaceuticals, Inc. (RCKT): Protect Your RightsContact Levi & Korsinsky Before August 11, 2025 - Newsfile
2025-07-30 | Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky to Join Class Action Before August 11, 2025 | NDAQ:RCKT | Press Release - Stockhouse
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - FinancialContent
Shareholders of Rocket Pharmaceuticals, Inc. Should Contact - GlobeNewswire
Investors In Rocket Pharmaceuticals, Inc. (RCKT): Protect Your RightsContact Levi & Korsinsky Before August 11, 2025 - Barchart.com
What recovery options are there for Rocket Pharmaceuticals Inc.AI Screener for Daily Stock Forecast - Newser
Signal strength of Rocket Pharmaceuticals Inc. Equity Warrant stock in tech scannersEntry Optimization Tool with Screener Logic - Newser
Rocket Pharmaceuticals Inc. Equity Warrant’s volatility index tracking explainedFree Conservative Long Term Growth Plans - Newser
Will Rocket Pharmaceuticals Inc. continue its uptrendBollinger Band Squeeze and Expansion Analysis - Newser
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy TrialHagens Berman - TradingView
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - PR Newswire
What’s the recovery path for long term holders of Rocket Pharmaceuticals Inc. Equity WarrantInvestment Timing Strategy with Market Filters - Newser
Is Rocket Pharmaceuticals Inc. reversing from oversold territoryRisk Adjusted Trade Signal Screening Tool - Newser
Using Python tools to backtest Rocket Pharmaceuticals Inc. strategiesFree High Yield Stock Screening Results - Newser
ROCKET PHARMACEUTICALS (RCKT) INVESTOR ALERT: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action - TradingView
RCKT INVESTOR DEADLINE: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
RCKT LAWSUIT ALERT: Levi & Korsinsky Notifies Rocket - GlobeNewswire
FDA Clinical Hold on RP-A501 Trial Triggers Rocket - GlobeNewswire
DEADLINE ALERT: Holzer & Holzer, LLC Reminds Investors of - GlobeNewswire
Rocket Pharmaceuticals, Inc. (RCKT) LawsuitInvestors Urged to Contact Levi & Korsinsky Before August 11, 2025 - ACCESS Newswire
Rocket Pharmaceuticals, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before August 11, 2025 to Discuss Your RightsRCKT - PR Newswire
What institutional flow reveals about Rocket Pharmaceuticals Inc. Equity WarrantDay Trading Setup and Momentum Analysis - Newser
Published on: 2025-07-28 05:44:07 - Newser
What institutional flow reveals about Rocket Pharmaceuticals Inc. Equity Warrant Predictive System for Long-Term Stock Forecast - Newser
How to recover losses in Rocket Pharmaceuticals Inc. Equity Warrant stock Free Exit Ready Momentum Stock Watchlist - Newser
Q3 EPS Estimate for Rocket Pharmaceuticals Raised by Analyst - Defense World
Rocket Pharmaceuticals’ (RCKT) Hold Rating Reiterated at Needham & Company LLC - Defense World
Canaccord Genuity Group Has Lowered Expectations for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price - Defense World
Bank of America Reiterates “Neutral” Rating for Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire
RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors - GlobeNewswire
Chardan Capital Lowers Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $12.00 - Defense World
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Rocket - GlobeNewswire
Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours - Benzinga
Rocket Pharmaceuticals (RCKT) Target Price Lowered by Canaccord Genuity | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals Inc. Equity Warrant Stock Analysis and ForecastFree Predictions - PrintWeekIndia
Deadline Alert: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire
Rocket Pharmaceuticals Inc. Stock Analysis and ForecastHigh-octane financial growth - PrintWeekIndia
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):